Moderate intensity statin

PreclinicalSmall molecule

Moderate intensity statin is one of 3 small molecule programs targeting Postoperative Recovery. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postoperative RecoveryCompleted

Postoperative RecoveryPreclinical

Completed

Competition

Competitive Landscape

7 competitors in Postoperative Recovery

#DrugCompanyPhaseTrials

Dalgan

AstraZeneca

Approved

1 2

Platelet-Rich Fibrin (PRF)

FFederal University of São Paulo

Preclinical

1 3

Moderate intensity statin

YYonsei University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Inflammatory Cytokines

NCT07485517

Clinical

Trials by Indication[1]

Prevention1 trial

Low- and Moderate-intensity Statin and Clinical Outcome of Primary Prevention in Individuals Aged >70 Years: the SCOPE-70 RCT Study

Recruiting·YYonsei University·Phase 4·NCT03770312·724 enrolled

Quality of Recovery1 trial

Comparison of Deep Neuromuscular Block and Moderate Neuromuscular Block on Quality of Recovery in Patients Undergoing Robotic Gastrectomy

Completed·YYonsei University·N/A·NCT02762890·56 enrolled

Patient Satisfaction1 trial

Deep vs Moderate Block: Impact on Operating Conditions & Patient Satisfaction

Withdrawn·—·Phase 4·NCT02794714

Shoulder pain1 trial

Neuromuscular Blockade on Shoulder Pain of Elderly

Completed·MM.D. Anderson Cancer Center·Phase 4·NCT03210376·100 enrolled

Postoperative Recovery1 trial

The Effect of Deep Neuromuscular Block on the Perioperative Stress Response Reduction and Postoperative Recovery Enhancement in Robot-assisted Stomach Cancer Surgery

Completed·YYonsei University·N/A·NCT03937440·46 enrolled

1 more indication

Inflammatory Cytokines1 trial

The Effect of Deep Versus Moderate Neuromuscular Blocking on Patients Undergoing Open Hysterectomy

Recruiting·MMenoufia University·Preclinical·NCT07485517·88 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Moderate intensity statin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Moderate intensity statin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Moderate intensity statin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYonsei University

Moderate intensity statin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Prevention1 trial

Quality of Recovery1 trial

Patient Satisfaction1 trial

Shoulder pain1 trial

Postoperative Recovery1 trial

Inflammatory Cytokines1 trial

References

Drug Info

Quick Facts

Related News